• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Cytek Biosciences Inc (NQ: CTKB )

    5.205 +0.195 (+3.89%)
    Streaming Delayed Price Updated: 2:29 PM EDT, Oct 14, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 414,549
    Open 5.000
    Bid (Size) 5.200 (20)
    Ask (Size) 5.210 (11)
    Prev. Close 5.010
    Today's Range 4.930 - 5.295
    52wk Range 3.800 - 9.870
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Cytek® Biosciences Brings Full Spectrum Profiling™ (FSP™) Technology to the Forefront at Major Clinical Conferences in the U.S. and Europe
    Industry Leaders to Explore Cytek’s Advanced Cell Analysis Solutions at ICCS and ESCCA 
    From Cytek Biosciences, Inc.
    Via GlobeNewswire
    Cytek® Biosciences Achieves ISO 13485 Certification at San Diego Reagent Manufacturing Facility
    Certification Emphasizes Unwavering Commitment to Quality and Is an Essential Step for U.S. Clinical Market Entry 
    From Cytek Biosciences, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -41.32%
    -41.32%
    1 Month
    +6.01%
    +6.01%
    3 Month
    -17.77%
    -17.77%
    6 Month
    -13.54%
    -13.54%
    1 Year
    +7.99%
    +7.99%

    More News

    Read More
    CTKB Stock Earnings: Cytek Biosciences Misses EPS, Misses Revenue for Q2 2024
    Via InvestorPlace
    Cytek® Biosciences Automates Panel Design with New Intelligent Algorithm
    From Cytek Biosciences, Inc.
    Via GlobeNewswire
    Cytek Biosciences Announces $50 Million Stock Repurchase Program
    From Cytek Biosciences, Inc.
    Via GlobeNewswire
    Cytek Biosciences to participate at the Goldman Sachs 45th Annual Global Healthcare Conference
    From Cytek Biosciences, Inc.
    Via GlobeNewswire
    1-Laser and 2-Laser 6-Color TBNK Reagents from Cytek® Biosciences Approved for Clinical Use in China
    From Cytek Biosciences, Inc.
    Via GlobeNewswire
    Cytek® Biosciences Adds Ability to Detect Subcellular Particles to Its Industry-Leading Cell Analysis Systems
    From Cytek Biosciences, Inc.
    Via GlobeNewswire
    CTKB Stock Earnings: Cytek Biosciences Misses EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    Cytek Biosciences Reports First Quarter 2024 Financial Results
    From Cytek Biosciences, Inc.
    Via GlobeNewswire
    Cytek® Biosciences to Spotlight Cell Analysis Solutions at Upcoming Conferences in the United States and Europe
    From Cytek Biosciences, Inc.
    Via GlobeNewswire
    Cytek Biosciences to Report First Quarter 2024 Financial Results on May 8, 2024
    From Cytek Biosciences, Inc.
    Via GlobeNewswire
    CTKB Stock Earnings: Cytek Biosciences Beats Revenue for Q4 2023
    Via InvestorPlace
    Cytek® Biosciences Names William McCombe Chief Financial Officer
    From Cytek Biosciences, Inc.
    Via GlobeNewswire
    Cytek® Biosciences Opens New Facility to Address Increasing Global Demand for Cutting-Edge Cell Analysis Solutions
    From Cytek Biosciences, Inc.
    Via GlobeNewswire
    Tesla, Spirit Airlines, New York Community Bancorp And Other Big Stocks Moving Lower On Monday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Via Benzinga
    Cytek Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook
    From Cytek Biosciences, Inc.
    Via GlobeNewswire
    Cytek Biosciences to Participate in Upcoming Investor Conferences
    From Cytek Biosciences, Inc.
    Via GlobeNewswire
    Cytek Biosciences to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
    From Cytek Biosciences, Inc.
    Via GlobeNewswire
    Cytek® Biosciences Signs Agreement with CRG and UPF to Accelerate Scientific Discoveries
    From Cytek Biosciences, Inc.
    Via GlobeNewswire
    Cytek Biosciences Announces Preliminary Full Year 2023 Revenue Results
    From Cytek Biosciences, Inc.
    Via GlobeNewswire
    Cytek Biosciences to present at the 42nd Annual J.P. Morgan Healthcare Conference
    From Cytek Biosciences, Inc.
    Via GlobeNewswire
    Cytek® Biosciences Introduces the Cytek Orion™ Reagent Cocktail Preparation System, the First-of-its-Kind Automated Cocktail Preparation Instrument for Flow Cytometry
    From Cytek Biosciences, Inc.
    Via GlobeNewswire
    Cytek's Full Spectrum Technology Stands Out In Cell Analysis Market, Bullish Analyst Says
    Via Benzinga
    Topics Supply Chain
    Exposures Supply Chain
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.